CTIS2024-512884-30-00进行中（未招募）1 期
A randomized phase III study comparing trastuzumab, pertuzumab plus docetaxel (TPD) followed by 3 cycles of chemotherapy to the current standard regimen as the treatments of early HER2-positive breast cancer - FBCSG-01-2007
HUS-Yhtymae0 个研究点目标入组 520 人开始时间: 2024年3月29日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 520
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
入选标准
- •Woman > 18 years of age, confirmed invasive HER2-positive breast cancer
排除标准
- •Presence of distant metastases, clinically significant cardiac disease
研究者
相似试验
进行中（未招募）
不适用
A randomized phase III study comparing trastuzumab plus docetaxel (HT) followed by 5-FU, epirubicin, and cyclophosphamide (FEC) to the same regimen followed by single-agent trastuzumab as adjuvant treatments for early breast cancer. The Synergism Or Long Duration (SOLD) Study. - SOLDEUCTR2007-002016-26-ISFinnish Braest Cancer Group3,000
进行中（未招募）
不适用
A randomized phase III study comparing trastuzumab plus docetaxel (HT) followed by 5-FU, epirubicin, and cyclophosphamide (FEC) to the same regimen followed by single-agent trastuzumab as adjuvant treatments for early breast cancer - SOLDEUCTR2007-002016-26-FIFinnish Breast Cancer Group3,000
进行中（未招募）
1 期
Comparison of two anti-HER2 agents plus chemotherapy with standard regimen as the treatments of breast cancer that expresses HER2Early HER-2 -positive breast cancerEUCTR2015-002323-25-FIFinnish Breast Cancer Group1,366
进行中（未招募）
1 期
Comparison of two anti-HER2 agents plus chemotherapy with standard regimen as the treatments of breast cancer that expresses HER2Early HER-2 -positive breast cancerEUCTR2015-002323-25-SEFinnish Breast Cancer Group1,366
进行中（未招募）
不适用
SOLDEUCTR2007-002016-26-SEFBCSG (Finish Breast Cancer Study Group)2,168